Romy Thomas

Romy Thomas

Auto-generated profile, based on publicly available information

Romy Thomas

Rudolf Boehm Institute of Pharmacology and Toxicology, Medical Faculty, Leipzig University, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2021 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
AIAli Işbilir
Ali Işbilir
RSRobert Serfling
Robert Serfling
JMJan Möller
Jan Möller
RTRomy Thomas
Romy Thomas
CFChiara De Faveri
Chiara De Faveri
PAPaolo Annibale
Paolo Annibale

14 January 2026 in Nature
Verified
Journal Article
Open access
PDF file
RTRomy Thomas
Romy Thomas
PJPauline S. Jacoby
Pauline S. Jacoby
CFChiara De Faveri
Chiara De Faveri
CDCécile Derieux
Cécile Derieux
ALAenne-Dorothea Liebing
Aenne-Dorothea Liebing
ABAndreas Bock
Andreas Bock
G-protein-coupled receptors (GPCRs) are key mediators of cell communication and represent the most important class of drug targets 1,2 . Biophysical studies with purified GPCRs in vitro have suggested that they exist in an equilibrium of distinct inactive and active states, which is modulated by ligands in an efficacy-dependent manner 3–11 . However, how efficacy is encoded and whether multiple receptor states occur in living cells remain unclear. Here we use genetic code expansion 12 and bioorthogonal labelling 13–16 to generate a panel of fluorescence-based biosensors for a prototypical GPCR, the M 2 muscarinic acetylcholine receptor (M 2 R). These biosensors enable real-time monitoring of agonist-promoted conformational changes across the receptor’s extracellular surface in intact cells. We demonstrate that different agonists produce equilibria of at least four distinct active states of the G-protein-bound M 2 R, each with a different ability to activate G proteins. The formation of these M 2 R–G-protein complexes occurs over 0.2–5 s along trajectories that involve both common and ligand-specific conformational changes and appear to determine G-protein selectivity. These observations reveal the molecular nature of ligand efficacy in intact cells. Selectively exploiting such different GPCR activation trajectories and conformational equilibria may open new avenues for GPCR drug discovery.